Atlas Trials

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

Clinical trial NCT04899271 · TERMINATED

Trial details

NCT number
NCT04899271
Sponsor
Dompé Farmaceutici S.p.A
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
New-onset Type 1 Diabetes
Start date
2020-12-14
Primary completion
2023-04-27
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.